Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease ...

TAG Therapeutics a biotechnology company developing precision medicines for diseases driven by telomere dysfunction, today announces the publication of compelling preclinical data supporting the ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...

United Therapeutics UTHR announced completing enrollment in the phase III TETON-PPF study evaluating Tyvaso (treprostinil) inhalation solution for the treatment of progressive pulmonary fibrosis (PPF) ...

A study has reported that “proton therapy” could become a new treatment option for lung cancer patients with idiopathic ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

CHICAGO, June 5, 2025 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF)'s, the nation's leading pulmonary fibrosis (PF) research, education, and advocacy organization, invites people living with ...

In a recent study published in The Lancet Respiratory Medicine, a team of researchers compared the efficacy of the controlled release of low-dose morphine as an antitussive treatment against that of a ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...

The emerging role of precision medicine in diagnosing and treating interstitial lung disease will take center stage during ...